ClinicalTrials.gg
TerminatedNCT04826237Updated Oct 29, 2026Results posted

Oral Statins and Protection From Hearing Loss

A Phase 4 interventional study of Statin and methylprednisolone in Sudden Sensorineural Hearing Loss, sponsored by Northwestern University. Terminated at 1 site in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by Northwestern University · Phase 4, Interventional, and Treatment

How we know

Why this study was terminated
Insufficient funding
Updated Oct 29, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
3
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Hearing Loss, Sudden with a site in United States — 1 open to participants now, 1 under way, none of them phase 3. Hearing Loss, Sudden · United States.

Enrollment
9th of 11
3 · median 30
Started
2023
the only one that year
Phase 4
Only one
of the 12
Registered
9th of 12
by date
Lead sponsor
1 of 12
Northwestern University

Among the 12 studies in Hearing Loss, Sudden with a site in United States, this one is the 9th largest by enrollment of the 11 interventional ones that give a count, is the only one that started in 2023, is the only one in phase 4, and was the 9th registered.

Hearing Loss, Sudden

66 studies on the registry are indexed under Hearing Loss, Sudden; 25 are open to participants now.

Browse Hearing Loss, Sudden studies →

Open to participants now

1 of the 12 studies in Hearing Loss, Sudden with a site in United States is open now. Recruiting first, the newest first:

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 10 Hearing Loss, Sudden studies recruiting now, 3 (30%) set no upper age limit and 5 (50%) stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Hearing Loss, Sudden with a site in United States, or all of them as a file.
02

Study summary

A small clinical trial for idiopathic sudden sensorineural hearing loss (ISSNHL). Will the addition of an oral statin to the standard treatment (oral methylprednesolone and the salvage therapy of intratympanic dexamethasone) improve the treatment outcome for patients with ISSNHL? This study will compare the two treatments and quantitatively evaluate hearing and speech discrimination and have the patients subjectively evaluate tinnitus.

Read the detailed description

After being informed about the study and potential risks, all patients diagnosed with idopathic sudden sensorineural hearing loss who do not meet the exclusion criteria and do meet the inclusion criteria, and who give written informed consent will be enrolled in the trial. A standard treatment for ISSNHL (oral methyprednisolone) will be given to half of the patients and the other half of the patients will receive the standard treatment plus either a placebo or a 7-day course of an HMG-CoA reductase inhibitor (a statin). Patients will return for follow up, the timing and further treatment of which will be determined by the response to the drugs. At each appointment, the patients will see the medical professional, have a hearing test, a speech in noise test, and self evaluate for tinnitus. If there is no improvement after 2 weeks, patient will be offered up to two intratympanic doses of dexamethasone, 10 days apart. This is a randomized, double-blind prospective study. Randomization of males will be separate from that of females.

03

Conditions studied

  • Sudden Sensorineural Hearing Loss

Keywords

  • deafness
  • statin
  • hearing loss
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient older than 18 years and younger than 81 years and
  • Diagnosed with one sided idiopathic sudden sensorineural hearing loss by physical examination, history, audiology, speech interpretation tests and tinnitus evaluation and
  • Seen in the clinic within the first 30 days after the onset of symptoms. and
  • Mean hearing threshold equal to or worse than >30 dB averaged across three consecutive frequencies.
  • Excellent English Speaking and Comprehension

Exclusion criteria

Exclusion Criteria:

  • Children
  • Prisoners
  • Pregnant women
  • Patients who have experienced similar prior events of SSNHL
  • Patients with bacterial infections, mycoplasma, Lyme disease, tuberculosis, syphilis, fungal infections,
  • inner ear disease
  • Middle ear inflammation or effusion
  • Ototoxic medication such as chemotherapy, loop diuretics, high dose aspirin, etc.
  • Head Trauma, lead poisoning
  • Genetic disorders affecting hearing
  • Mitochondrial disorders, including MELAS (metabolic encephalopathy, lactic acidosis, and stroke-like episodes), stroke, Cogan's syndrome
  • Neoplastic (neurofibromatosis II, bilateral vestibular schwannomas, carcinomatous meningitis, intravascular lymphomatosis, others)
  • Sarcoidosis
  • Hyperviscosity syndrome
  • Diabetes
  • Use of statins within the last 1 month
  • Allergy, or intolerance to any components of the study medication
  • Prior tinnitus
  • Prior otologic surgery other than ventilation tubes
  • History of drug abuse or alcoholism within the prior 2 years
  • Any psychiatric syndrome requiring treatment with neuroleptics, antidepressants, hypnotics or anxiolytics
  • Severe systemic neurologic disease (epilepsy, Parkinson's, dementia/Alzheimers, multiple sclerosis
  • Oral treatment within the preceding 2 weeks
  • Heart disease or TIAs
  • Chronic kidney failure
  • , or C
  • Active shingles
  • Skull, facial or temporal bone anomalies

COVID-19 immunization within the last 30 days Patients that medically cannot be treated with corticosteroids or statins or that the physician feels have possible coexisting problems that would cause participation in the study to be unsafe

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
3 participants (actual)

Study arms

  • Experimental
    Statin

    Methylprednisolone+statin (identity and dose to be determined before Trial Begins) Oral methyprednisolone, tapering dose over 11 days, beginning at 16 mg 4 x a day; Oral statin 1 dose per day for 7 days, beginning with the first dose of methylprednisolone: If no improvement after two weeks, offer up to 2 doses intratympanic dexamethasone (10 mg/cc) 10 days apart.

    Drug: Statin · Drug: methylprednisolone · Drug: dexamethasone

  • Placebo comparator
    Placebo

    Methylprednisolone+ placebo. Oral methyprednisolone, tapering dose over 11 days, beginning at 16 mg 4 x a day; Oral placebo 1 dose per day for 7 days, beginning with the first dose of methylprednisolone If no improvement after two weeks, offer up to 2 doses intratympanic dexamethasone (10 mg/cc) 10 days apart.

    Drug: methylprednisolone · Drug: dexamethasone · Drug: Placebo

Interventions

  • DrugStatinsStudies of StatinsStatins pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Oral dose to be taken with methylprednisolone

    Also known as: HMG-coA reductase Inhibitor

  • oral dose, standard of care

    Also known as: medrol

  • Drug for intratympanic administration

    Also known as: decadron

  • DrugPlacebo

    Capsule the same as for statins but without statin

06

What researchers measure

Primary outcomes

  1. Articulation Index

    Estimates how much of normal conversational speech is audible to that ear. Max score is 100%, min score is 0%

    Time frame: 2 weeks, 4 weeks, 6 weeks

  2. Word Recognition Score

    Measures how many words you correctly repeat when speech is presented at an audible level. * 90-100% = Excellent * 80-89% = Good * 70-79% = Fair * Below 70% = Significant difficulty

    Time frame: 2 weeks, 4 weeks, 6 weeks

  3. Tinnitus Handicap Inventory (THI)

    Tinnitus Handicap Inventory (THI) is a scale which measures severity of tinnitus. Minimum score is 0 and maximum score is 100. A higher score indicates greater severity of symptoms. Additionally, the numerical scores are divided into the following grades: Grade 1 (Slight): 0-16 Grade 2 (Mild): 18-36 Grade 3 (Moderate): 38-56 Grade 4 (Severe): 58-76 Grade 5 (Catastrophic): 78-100

    Time frame: 2 weeks, 6 weeks

07

Results

Posted Oct 29, 2026
Limitations and caveats
Low enrollment limits significance of the study data.

Participant flow

Patients were recruited from the Otolaryngology Practice at Northwestern University. Some were recruited by a website description of the study.

Participant flow — Overall Study
MilestoneStatinPlacebo
Started21
Completed21
Not completed00

Outcome measures

PrimaryArticulation Index

Estimates how much of normal conversational speech is audible to that ear. Max score is 100%, min score is 0%

Time frame:
2 weeks, 4 weeks, 6 weeks
Reported as:
Mean · percentage of speech sounds
Articulation Index
percentage of speech soundsStatinPlacebo
2 weeks Right ear Male86 (86 to 86)—
2 weeks Left ear Male100 (100 to 100)—
4 weeks Right ear Male93 (93 to 93)—
4 weeks Left ear Male100 (100 to 100)—
6 weeks Right ear Male100 (100 to 100)—
6 weeks Left ear Male100 (100 to 100)—
2 weeks Right ear Female100 (100 to 100)100 (100 to 100)
2 weeks Left ear Female37 (37 to 37)100 (100 to 100)
4 weeks Right ear Female100 (100 to 100)100 (100 to 100)
4 weeks Left ear Female80 (80 to 80)100 (100 to 100)
6 weeks Right ear Female100 (100 to 100)100 (100 to 100)
6 weeks Left ear Female99 (99 to 99)99 (99 to 99)
PrimaryWord Recognition Score

Measures how many words you correctly repeat when speech is presented at an audible level. * 90-100% = Excellent * 80-89% = Good * 70-79% = Fair * Below 70% = Significant difficulty

Time frame:
2 weeks, 4 weeks, 6 weeks
Reported as:
Mean · percentage of words
Word Recognition Score
percentage of wordsStatinPlacebo
2 weeks Right ear Male96 (96 to 96)—
2 weeks Left ear Male100 (100 to 100)—
4 weeks Right ear Male100 (100 to 100)—
4 weeks Left ear Male100 (100 to 100)—
6 weeks Right ear Male100 (100 to 100)—
6 weeks Left ear Male100 (100 to 100)—
2 weeks Right ear Female100 (100 to 100)100 (100 to 100)
2 weeks Left ear Female88 (88 to 88)100 (100 to 100)
4 weeks Right ear Female100 (100 to 100)100 (100 to 100)
4 weeks Left ear Female68 (68 to 68)96 (96 to 96)
6 weeks Right ear Female100 (100 to 100)100 (100 to 100)
6 weeks Left ear Female100 (100 to 100)100 (100 to 100)
PrimaryTinnitus Handicap Inventory (THI)

Tinnitus Handicap Inventory (THI) is a scale which measures severity of tinnitus. Minimum score is 0 and maximum score is 100. A higher score indicates greater severity of symptoms. Additionally, the numerical scores are divided into the following grades: Grade 1 (Slight): 0-16 Grade 2 (Mild): 18-36 Grade 3 (Moderate): 38-56 Grade 4 (Severe): 58-76 Grade 5 (Catastrophic): 78-100

Time frame:
2 weeks, 6 weeks
Reported as:
Mean · score on a scale
Tinnitus Handicap Inventory (THI)
score on a scaleStatinPlacebo
2 weeks Male0 (0 to 0)—
6 weeks Male0 (0 to 0)—
2 weeks Female20 (20 to 20)16 (16 to 16)
6 weeks Female4 (4 to 4)0 (0 to 0)

Adverse events

Collected over Until the end of the study (up to 4 months). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Statin0/2 (0%)0/2 (0%)0/2 (0%)
Placebo0/1 (0%)0/1 (0%)0/1 (0%)

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)StatinPlaceboTotal
<=18 years000
Between 18 and 65 years213
>=65 years000
Sex: Female, Male
Sex: Female, Male(Participants)StatinPlaceboTotal
Female112
Male101
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)StatinPlaceboTotal
Count of participants——0
Region of Enrollment
Region of Enrollment(Participants)StatinPlaceboTotal
United States213
Air Conduction Pure Tone Average
Air Conduction Pure Tone Average(dB HL)StatinPlaceboTotal
Right ear Males73 (73 to 73)—73 (73 to 73)
Left ear Males15 (15 to 15)—15 (15 to 15)
Right ear Females10 (10 to 10)12 (12 to 12)11 (10 to 12)
Left ear Females72 (72 to 72)80 (80 to 80)76 (72 to 80)
Bone Conduction Pure Tone Average
Bone Conduction Pure Tone Average(dB HL)StatinPlaceboTotal
Right ear Males67 (67 to 67)—67 (67 to 67)
Left ear Males13 (13 to 13)—13 (13 to 13)
Right ear Females10 (10 to 10)2 (2 to 2)6 (2 to 10)
Left ear Females73 (73 to 73)67 (67 to 67)70 (67 to 73)
Articulation Index
Articulation Index(percentage)StatinPlaceboTotal
Right ear Male3 (3 to 3)—3 (3 to 3)
Left ear Male100 (100 to 100)—100 (100 to 100)
Right ear Female100 (100 to 100)100 (100 to 100)100 (100 to 100)
Left ear Female0 (0 to 0)0 (0 to 0)0 (0 to 0)
Tinnitus Handicap Inventory (THI)
Tinnitus Handicap Inventory (THI)(score on a scale)StatinPlaceboTotal
Male0 (0 to 0)—0 (0 to 0)
Female24 (24 to 24)24 (24 to 24)24 (24 to 24)

1 further baseline measures are reported on the registry.

08

Study locations

1 site
  • Northwestern Memorial Hospital
    Chicago, Illinois 60611, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Only unidentified data will be shared

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2023 to primary completion in Oct 2025, 32 months.

Results were first posted in Oct 2026, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 24, 2021
First posted
Apr 1, 2021
StartActual
Feb 9, 2023
Primary completionActual
Oct 30, 2025
CompletionActual
Oct 30, 2025
Results first posted
Oct 29, 2026
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 29, 2026
Primary outcomes
3 added, 3 removed
What changed in the outcomes
  • AddedArticulation IndexTime frame: 2 weeks, 4 weeks, 6 weeks
  • AddedWord Recognition ScoreTime frame: 2 weeks, 4 weeks, 6 weeks
  • AddedTinnitus Handicap Inventory (THI)Time frame: 2 weeks, 6 weeks
  • RemovedChange in Pure Tone Audiometry for Hearing AssessmentTime frame: At the initiation and the end of the study (up to 4 months after initial assessment)
  • RemovedChange in Speech DiscriminationTime frame: At the initiation and the end of the study, up to 4 months after initial assessment
  • RemovedChange in Tinnitus ScoreTime frame: AT the initiation and the end of the study, up to 4 months after initial assessment
Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    Results posted
    Primary outcomes 3 added, 3 removed
    What changed in the outcomes
    • AddedArticulation IndexTime frame: 2 weeks, 4 weeks, 6 weeks
    • AddedWord Recognition ScoreTime frame: 2 weeks, 4 weeks, 6 weeks
    • AddedTinnitus Handicap Inventory (THI)Time frame: 2 weeks, 6 weeks
    • RemovedChange in Pure Tone Audiometry for Hearing AssessmentTime frame: At the initiation and the end of the study (up to 4 months after initial assessment)
    • RemovedChange in Speech DiscriminationTime frame: At the initiation and the end of the study, up to 4 months after initial assessment
    • RemovedChange in Tinnitus ScoreTime frame: AT the initiation and the end of the study, up to 4 months after initial assessment
    + 1 other change: index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04826237
Responsible party
Sponsor
First posted
Apr 1, 2021
Start date
Feb 9, 2023
Primary completion
Oct 30, 2025
Completion
Oct 30, 2025
Results posted
Oct 29, 2026
Last update
Oct 29, 2026

Study contacts

Donna Whitlon, Ph.D.
principal investigator · Northwestern University

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Statins

Start the discussion